Cisplatin regulates SH-SY5Y cell growth through downregulation of BDNF via miR-16

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2343-2349

  Sun, Yun Xiao ^a,b   Yang, Jian ^c   Wang, Ping Yu ^b   Li, You Jie ^b   Xie, Shu Yang ^a,b   Sun, Ruo Peng ^a  

^a SHANDONG UNIVERSITY   (China)

^b BINZHOU MEDICAL UNIVERSITY   (China)

^c Yantai Central Blood Station   (China)

Author keywords

BDNF; Cell proliferation; Cisplatin; Gene expression; MicroRNAs; Neuroblastoma

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CISPLATIN; MICRORNA 16; SODIUM CHLORIDE;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; RNA ANALYSIS; RNA SYNTHESIS; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICRORNAS; NEUROBLASTOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885064982     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2731     Document Type: Article

References (38)

1. London WB, Castleberry RP, Matthay KK, et al: Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 23: 6459-6465, 2005.
2. Maris JM: Recent advances in neuroblastoma. N Engl J Med 362: 2202-2211, 2010.
3. Chu CM, Rasalkar DD, Hu YJ, Cheng FW, Li CK and Chu WC: Clinical presentations and imaging findings of neuroblastoma beyond abdominal mass and a review of imaging algorithm. Br J Radiol 84: 81-91, 2011.
4. Pavlidis N, Stahel R, Clarke M and Djulbegovic B: Cancer treatment reviews welcomes submission of the Cochrane Reviews. Cancer Treat Rev 32: 243-244, 2006.
5. Verissimo CS, Molenaar JJ, Fitzsimons CP and Vreugdenhil E: Neuroblastoma therapy: what is in the pipeline? Endocr Relat Cancer 18: R213-R231, 2011.
6. Hara J: Development of treatment strategies for advanced neuroblastoma. Int J Clin Oncol 17: 196-203, 2012.
7. Arévalo JC and Wu SH: Neurotrophin signaling: many exciting surprises! Cell Mol Life Sci 63: 1523-1537, 2006.
8. Huang EJ and Reichardt LF: Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 72: 609-642, 2003.
9. Soppet D, Escandon E, Maragos J, et al: The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. Cell 65: 895-903, 1991.
10. Odate S, Nakamura K, Onishi H, et al: TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma. Lung Cancer 79: 205-214, 2013.
11. Dionne CA, Camoratto AM, Jani JP, et al: Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 4: 1887-1898, 1998.
12. Miknyoczki SJ, Lang D, Huang L, Klein-Szanto AJ, Dionne CA and Ruggeri BA: Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior. Int J Cancer 81: 417-427, 1999.
13. Huang YT, Lai PC, Wu CC, et al: BDNF mediated TrkB activation is a survival signal for transitional cell carcinoma cells. Int J Oncol 36: 1469-1476, 2010.
14. Sclabas GM, Fujioka S, Schmidt C, et al: Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res 11: 440-449, 2005.
15. Patani N, Jiang WG and Mokbel K: Brain-derived neurotrophic factor expression predicts adverse pathological and clinical outcomes in human breast cancer. Cancer Cell Int 11: 23, 2011.
16. Chen PS, Su JL and Hung MC: Dysregulation of microRNAs in cancer. J Biomed Sci 19: 90, 2012.
17. Zhou H, Guo JM, Lou YR, et al: Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J Mol Med 88: 709-717, 2010.
18. Teshima K, Nara M, Watanabe A, et al: Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma. Oncogene: May 20, 2013 (Epub ahead of print). doi: 10.1038/onc.2013.177.
19. Cece R, Barajon I and Tredici G: Cisplatin induces apoptosis in SH-SY5Y human neuroblastoma cell line. Anticancer Res 15: 777-782, 1995.
20. Zhang YX, Yue Z, Wang PY, et al: Cisplatin upregulates MSH2 expression by reducing miR-21 to inhibit A549 cell growth. Biomed Pharmacother 67: 97-102, 2013.
21. Middlemas DS, Kihl BK, Zhou J and Zhu X: Brain-derived neurotrophic factor promotes survival and chemoprotection of human neuroblastoma cells. J Biol Chem 274: 16451-16460, 1999.
22. Numakawa T, Suzuki S, Kumamaru E, Adachi N, Richards M and Kunugi H: BDNF function and intracellular signaling in neurons. Histol Histopathol 25: 237-258, 2010.
23. Xiong L, Deng X, Wen Y, Yang Z and Miao X: Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions. World J Surg Oncol 11: 80, 2013.
24. Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Annu Rev Med 60: 167-179, 2009.
25. Guo WG, Zhang Y, Ge D, et al: Bioinformatics analyses combined microarray identify the desregulated microRNAs in lung cancer. Eur Rev Med Pharmacol Sci 17: 1509-1516, 2013.
26. Kefas B, Godlewski J, Comeau L, et al: microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68: 3566-3572, 2008.
27. Xiong S, Zheng Y, Jiang P, Liu R, Liu X and Chu Y: MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci 7: 805-814, 2011.
28. Bhattacharya R, Nicoloso M, Arvizo R, et al: MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res 69: 9090-9095, 2009.
29. Bonci D, Coppola V, Musumeci M, et al: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271-1277, 2008.
30. Ma Q, Wang X, Li Z, et al: microRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway. Oncol Rep 29: 1652-1658, 2013.
31. Lee ST, Chu K, Jung KH, et al: miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann Neurol 72: 269-277, 2012.
32. Mellios N, Huang HS, Grigorenko A, Rogaev E and Akbarian S: A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex. Hum Mol Genet 17: 3030-3042, 2008.
33. Mellios N, Huang HS, Baker SP, Galdzicka M, Ginns E and Akbarian S: Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol Psychiatry 65: 1006-1014, 2009.
34. Imam JS, Plyler JR, Bansal H, et al: Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One 7: e52397, 2012.
35. Xiang Q, Tang H, Yu J, Yin J, Yang X and Lei X: MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2. Pharmazie 68: 274-281, 2013.
36. Chauffert B, Dimanche-Boitrel MT, Garrido C, et al: New insights into the kinetic resistance to anticancer agents. Cytotechnology 27: 225-235, 1998.
37. Liu L, Lian J, Zhang H, et al: MicroRNA-302a sensitizes testicular embryonal carcinoma cells to cisplatin-induced cell death. J Cell Physiol: April 27, 2013 (Epub ahead of print). doi: 10.1002/jcp.24394.
38. Ryan J, Tivnan A, Fay J, et al: MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer 107: 967-976, 2012.